Quick Answer
Akari Therapeutics Plc reported Research And Development Expense of $2.82 million for the year ending 2025.
- Akari Therapeutics Plc showed a decrease of -59.7% in Research And Development Expense from 2024 to 2025.
- This data is from Akari Therapeutics Plc's annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $800.0 thousand | Q2 2014: $1.54 million | Q3 2014: $162.6 thousand | Q1 2015: $1.55 million | Q2 2015: $142.0 thousand | Q3 2015: $1.31 million | Q1 2016: $1.50 million | Q1 2023: $1.73 million | Q2 2023: $1.52 million | Q3 2023: -$314.0 thousand | Q1 2024: $2.28 million | Q2 2024: $3.31 million | Q3 2024: $143.0 thousand | Q1 2025: $813.0 thousand | Q2 2025: $667.0 thousand | Q3 2025: $249.0 thousand.
- Over the full 15 years of available data (2011 to 2025), Akari Therapeutics Plc's Research And Development Expense has grown by 234.7%.
- Historical annual values: Fiscal year 2025: $2.82 million | Fiscal year 2024: $6.98 million | Fiscal year 2023: $5.45 million | Fiscal year 2022: $9.56 million | Fiscal year 2021: $9.13 million | Fiscal year 2020: $8.82 million | Fiscal year 2019: $8.74 million | Fiscal year 2018: $11.80 million | Fiscal year 2017: $23.29 million | Fiscal year 2016: $17.31 million | Fiscal year 2015: $5.80 million | Fiscal year 2014: $1.62 million | Fiscal year 2013: $1.28 million | Fiscal year 2012: $1.48 million | Fiscal year 2011: $841.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: